{
  "disease_name": "Severe combined immunodeficiency due to adenosine deaminase deficiency",
  "orpha_code": "277",
  "drugs": [
    {
      "name": "STRIMVELIS",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/459556?name=277&mode=orpha&region=",
      "regulatory_id": "459556",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "STRIMVELIS(Tradename                        - 26/05/2016)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "STRIMVELIS(Tradename                        - 26/05/2016)",
        "(Tradename                        - 26/05/2016)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/459552?name=277&mode=orpha&region=&status=all",
          "text": "STRIMVELIS",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/459556?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene",
      "substance_url": "/en/drug/substance/330859?name=277&mode=orpha&region=&status=all",
      "substance_id": "330859",
      "regulatory_url": "/en/drug/regulatory/356813?name=277&mode=orpha&region=",
      "regulatory_id": "356813",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene(Medicinal product                        - 07/06/2013)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene(Medicinal product                        - 07/06/2013)",
        "(Medicinal product                        - 07/06/2013)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/330859?name=277&mode=orpha&region=&status=all",
          "text": "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/356813?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene",
      "substance_url": "/en/drug/substance/65878?name=277&mode=orpha&region=&status=all",
      "substance_id": "65878",
      "regulatory_url": "/en/drug/regulatory/133992?name=277&mode=orpha&region=",
      "regulatory_id": "133992",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene(Medicinal product                        - 26/08/2005)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene(Medicinal product                        - 26/08/2005)",
        "(Medicinal product                        - 26/08/2005)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/65878?name=277&mode=orpha&region=&status=all",
          "text": "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133992?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "REVCOVI",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/528458?name=277&mode=orpha&region=",
      "regulatory_id": "528458",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "REVCOVI(Tradename                        - 10/05/2018)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "REVCOVI(Tradename                        - 10/05/2018)",
        "(Tradename                        - 10/05/2018)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/528454?name=277&mode=orpha&region=&status=all",
          "text": "REVCOVI",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/528458?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "ADAGEN",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131201?name=277&mode=orpha&region=",
      "regulatory_id": "131201",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "ADAGEN(Tradename                        - 21/03/1990)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "ADAGEN(Tradename                        - 21/03/1990)",
        "(Tradename                        - 21/03/1990)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/100846?name=277&mode=orpha&region=&status=all",
          "text": "ADAGEN",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131201?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA",
      "substance_url": "/en/drug/substance/412879?name=277&mode=orpha&region=&status=all",
      "substance_id": "412879",
      "regulatory_url": "/en/drug/regulatory/412881?name=277&mode=orpha&region=",
      "regulatory_id": "412881",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA(Medicinal product                        - 21/10/2014)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA(Medicinal product                        - 21/10/2014)",
        "(Medicinal product                        - 21/10/2014)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/412879?name=277&mode=orpha&region=&status=all",
          "text": "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/412881?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Pegademase bovine",
      "substance_url": "/en/drug/substance/100845?name=277&mode=orpha&region=&status=all",
      "substance_id": "100845",
      "regulatory_url": "/en/drug/regulatory/132187?name=277&mode=orpha&region=",
      "regulatory_id": "132187",
      "orpha_substance_code": "ORPHA:277",
      "details": [
        "Pegademase bovine(Medicinal product                        - 29/05/1984)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "Pegademase bovine(Medicinal product                        - 29/05/1984)",
        "(Medicinal product                        - 29/05/1984)",
        "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/100845?name=277&mode=orpha&region=&status=all",
          "text": "Pegademase bovine",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/277",
          "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/132187?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "DEQSIGA",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/700589?name=277&mode=orpha&region=",
      "regulatory_id": "700589",
      "orpha_substance_code": "ORPHA:101997",
      "details": [
        "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
        "DEQSIGA(Tradename                        - 02/05/2025)",
        "(Tradename                        - 02/05/2025)",
        "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/700586?name=277&mode=orpha&region=&status=all",
          "text": "DEQSIGA",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/3002",
          "text": "ORPHA:3002 Immune thrombocytopenia",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/2331",
          "text": "ORPHA:2331 Kawasaki disease",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/2103",
          "text": "ORPHA:2103 Guillain-Barré syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/2932",
          "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/641",
          "text": "ORPHA:641 Multifocal motor neuropathy",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/101997",
          "text": "ORPHA:101997 Primary immunodeficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/700589?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US",
        "EU"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=277&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=277&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=277&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=277&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "HIZENTRA",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/353616?name=277&mode=orpha&region=",
      "regulatory_id": "353616",
      "orpha_substance_code": "ORPHA:183660",
      "details": [
        "HIZENTRA(Tradename                        - 14/04/2011)Disease(s) concernedORPHA:101977 Immunodeficiency predominantly affecting antibody productionORPHA:183660 Severe combined immunodeficiency",
        "HIZENTRA(Tradename                        - 14/04/2011)",
        "(Tradename                        - 14/04/2011)",
        "Disease(s) concernedORPHA:101977 Immunodeficiency predominantly affecting antibody productionORPHA:183660 Severe combined immunodeficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/353563?name=277&mode=orpha&region=&status=all",
          "text": "HIZENTRA",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/101977",
          "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/183660",
          "text": "ORPHA:183660 Severe combined immunodeficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/353616?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=277&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=277&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=277&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=277&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=277&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=277&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=277&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=277&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=277&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=277&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=277&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=277&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
      "substance_url": "/en/drug/substance/392978?name=277&mode=orpha&region=&status=all",
      "substance_id": "392978",
      "regulatory_url": "/en/drug/regulatory/688391?name=277&mode=orpha&region=",
      "regulatory_id": "688391",
      "orpha_substance_code": "ORPHA:183660",
      "details": [
        "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene(Medicinal product                        - 17/09/2024)Disease(s) concernedORPHA:183660 Severe combined immunodeficiency",
        "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene(Medicinal product                        - 17/09/2024)",
        "(Medicinal product                        - 17/09/2024)",
        "Disease(s) concernedORPHA:183660 Severe combined immunodeficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/392978?name=277&mode=orpha&region=&status=all",
          "text": "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/183660",
          "text": "ORPHA:183660 Severe combined immunodeficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/688391?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=277&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=277&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=277&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=277&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=277&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=277&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=277&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=277&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=277&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=277&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=277&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=277&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=277&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:03:48.249974",
  "run_number": 1,
  "total_drugs_found": 20,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Severe+combined+immunodeficiency+due+to+adenosine+deaminase+deficiency&orphaCode=277&name=277&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Severe combined immunodeficiency due to adenosine deaminase deficiency",
    "orphaCode": "277",
    "name": "277",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}